The future of T-cell manufacturing for immunotherapy – an interview with Dr. Ohad Karnieli
Cancer treatment has evolved in recent years from unspecific aggressive treatments, such as radiotherapy and chemotherapy, to new and more specific immune therapies. In recent years, new therapies called immune cell therapy or Adoptive Cell Transfer (ACT) have evolved. These therapies aim to activate and “educate” the immune system to attack the tumor. CAR-T (Chimeric Antigen Receptor) is one such therapy in which T cells from the patient are “engineered” outside the body, activated, expanded, and reinfused to the patient. Such therapies have shown unprecedented clinical efficacy in Leukemia where above 80% of end-stage patients showed remission. The problem is, these treatments...
Read More